Paxalisib safety, tolerability, recommended phase 2 dose, pharmacokinetics, and clinical activity were evaluated in patients with newly-diagnosed GBM with unmethylated MGMT promoter status as adjuvant therapy following surgical resection and chemoradiation with temozolomide. Here, MGMT is linked to glioblastoma.